Health Trials

Gastroenteropancreatic Nec Gep Nec

2

Review clinical trials related to Gastroenteropancreatic Nec Gep Nec. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)

This is a first-in-human (FIH), open-label, Phase 1 study designed to evaluate the safety, pharmacokinetics (PK), and preliminary efficacy of ML261, an autologous potency enhanced anti-DLL3 CAR T cell therapy, in participants with R/R SCLC or select NECs

Participants needed: 110
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Moonlight Bio, IncUpdated: Jun 25, 2026Locations: 5
Eligibility criteria

≥18 years of age at the time of signing the ICF [+6]

Previous systemic anti-cancer therapies within the timeframes, as specified in t... [+15]

Read more
Status: Recruiting

Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[212Pb\]Pb-MP0712, in patients aged ≥18 years with Small Cell Lung Cancer and other locally advanced or metastatic DLL3 positive tumors.

Participants needed: 138
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Molecular Partners AGUpdated: May 22, 2026Locations: 5
Eligibility criteria

Age ≥ 18 years old [+15]

Uncontrolled intercurrent illness [+4]

Read more